Table of Contents Table of Contents
Previous Page  79 / 154 Next Page
Information
Show Menu
Previous Page 79 / 154 Next Page
Page Background

A B S T R A C T S

S49

Median survival for elderly colorectal cancer was 43.38

months and 12.51 months for elderly pancreatic cancer.

Conclusion:

Despite geriatric parameters, adapted

FOLFIRINOX regimen seemed to have higher manageable

toxicities than younger with a particular attention to

neutropenia and diarrhea. Median survival in this metastatic

pancreatic population was similar to younger, and seemed to

be better in metastatic colorectal cancer than published.

mFOLFIRINOX can be administered in elderly with GCSF

prophylaxis to improve survival.

References

:

[1] Conroy,T et al. Folfirinox versus gemcitabine for metastatic

pancreatic cancer. N Engl J Med 2011;364:1817-25.

[2] Ychou et al. METHEP 2. Abstract 3512. ASCO 2016.

[3] Papamichael D et al. Treatment of colorectal cancer in

older patients : International Society of Geriatric oncology

(SIOG): consensus recommendations 2013. Ann Oncol 2015.

[4] Higuera et al. Management of pancreatic cancer in the

elderly. World J Gastroenterol 2016 January 14; 22(2): 764-

775

Disclosure of interest:

None declared

Keywords:

Folfirinox regimen, pancreatic and colorectal

elderly patients, survival, tolerance

P024

GERIATRIC ASSESSMENT AND FUNCTIONAL DECLINE IN

OLDER PATIENTS WITH LUNG CANCER

L. Decoster

1,

*, C. Kenis

2

, D. Schallier

1

, J. Vansteenkiste

2

,

K. Nackaerts

2

, L. Vanacker

1

, N. Vandewalle

1

, J. Flamaing

2

,

J. Lobelle

3

, K. Milisen

4

, J. De Grève

1

, H. Wildiers

2

1

UZ Brussel, Jette,

2

UZ Leuven, Leuven,

3

Consultant in statistics,

Beernem,

4

KU Leuven, Leuven, Belgium

Introduction:

Physicians treating lung cancer are con-

fronted with an expanding heterogeneous group of older

patients. Treatment of these patients is complex and focusses

on improving quality of life and prolonging overall survival

(OS). For this reason, maintenance of functional status (FS) is

a key endpoint.

Objectives:

The aim of the present study is to evaluate

the role of geriatric screening and geriatric assessment (GA)

as well as the evolution of FS in older patients 2-3 months

after the diagnosis of lung cancer, and to identify predictors

associated with functional decline and OS.

Methods:

Patients

70 years with a new diagnosis of

lung cancer in which a geriatric screening and a GA were

performed, were included. At baseline, all patients underwent

a uniform GA including FS measured by Activities of Daily

Living (ADL) and Instrumental Activities of Daily Living

(IADL). FS of patients was reassessed by repeating ADL and

IADL 2-3 months after diagnosis to define functional decline.

OS was collected. Determination of predictors of functional

decline on ADL and IADL and of OS was performed by

univariate and multivariable logistic and Cox regression.

Results:

245 patients with lung cancer were included from

October 2009 till January 2015. Median age was 76 years and

the majority of patients were male (72%) and had stage IV

disease (58%). Treatment consisted of surgery in 20 patients

(8%), radiotherapy in 105 patients (43%) of which neoadjuvant

in 1 patient, 66 curative in patients and palliative in 38 patients

and chemotherapy or targeted therapy in 125 patients (51%)

of which platinum doublet in 94 patients, monotherapy in

24 patients and targeted therapy in 6 patients. Forty-one

patients (17%) received only best supportive care. At baseline,

the screening tools G8 and Flemish version of triage risk

tool (fTRST) were abnormal (i.e.

14 and

1 respectively) in

respectively 91% and 83% of the patients. GA deficiencies were

observed in all domains but most prominent for fatigue (82%),

comorbidities (78%) and nutrition (76%). At baseline, ADL

and IADL impairments were detected in 126/245 (51%) and

154/245 (63%) of patients respectively. At follow-up, ADL and

IADL data were available for 145 patients. Functional decline

for ADL was observed in 23% (95%CI 16,2; 29,9) and for IADL

in 45% (95%CI 36,9;53,1) of patients. In multivariable analysis,

radiotherapy was predictive for ADL decline 2-3 months after

diagnosis. No other predictive factors for ADL or IADL were

identified. At the time of analysis, 45 out of 245 patients (18%)

were alive. In multivariable Cox regression, stage, gender and

age were predictive for survival .

Conclusion:

Older patients with lung cancer are a high

risk population which frequently presents at diagnosis with

deficiencies in all geriatric domains. Screening tools are

abnormal in almost 90% of patients, indicating that in this

subpopulation it might be indicated to perform GA in all

patients. During treatment functional decline is observed

in almost half of the patients, more prominently for IADL.

Functional decline on ADL at 2-3 months may be predicted

by radiotherapy, possibly related to the acute toxicities of this

treatment. Further follow-up at later time points is warranted

in order to investigate the evolution of functional decline.

None of the screening tools (G8, fTRST and ECOG-PS) nor the

specific domains of the GA were predictive for functional

decline or survival. Further research should focus on the role

of GA and interventions on evolution of quality of life.

Disclosure of interest:

None declared

Keywords:

Functional decline, geriatric assessment, older

lung cancer

P025

UTILITY OF GERIATRIC ASSESSMENT IN ELDERLY PATIENTS

WITH LOCALLY ADVANCED LUNG CANCER TO BE TREATED

WITH CONCURRENT CHEMORADIATION

M. T. Antonio Rebollo

1,

*, J. Saldaña

2

, J. Linares

2

, M. D. Arnaiz

2

,

J. C. Rufinelli

2

, J. Gonzalez-Barboteo

2

, V. Navarro

3

, A. Navarro

4

,

F. Cardenal

2

, E. Nadal

2

1

Medical Oncology, Institut Català d’Oncologia. Hospital Duran i

Reynals,

2

Medical Oncology,

3

Clinical Research Unit,

4

Radiotherapy

Oncology, Institut Català d’Oncologia-Hospital Duran i Reynals,

Barcelona, Spain

Introduction:

Because of the progressive aging of the

population, the number of elderly patients with NSCLC is